Loading organizations...
§ Private Profile · One Main Street, Cambridge MA 02142
Launchpad Therapeutics is a technology company.
Launchpad Therapeutics develops novel anti-cancer therapeutics, leveraging an AI-driven and structure-based drug discovery platform. The company focuses on creating early mutant-selective antibody programs designed to deliver cancer cell-specific antibodies. Its core capability lies in its platform's unique ability to target specific cancer mutations, aiming to improve clinical outcomes.
The company was founded in 2022 by Anna Kohlmann and Ken Geles, emerging as a spinout from Black Diamond Therapeutics. This origin provided a foundational insight into advancing targeted oncology treatments through innovative antibody development. Based in Warwick, United States, the founders’ expertise drives the strategic direction of their therapeutic pipeline.
Launchpad Therapeutics aims its products at patients suffering from various cancers, with a particular focus on improving treatment outcomes for those with brain tumors. The company’s long-term vision centers on advancing a portfolio of targeted biologic programs to address unmet needs in oncology, striving to provide more effective and precise treatment options for cancer patients.
Launchpad Therapeutics has raised $30.0M across 1 funding round.
Launchpad Therapeutics has raised $30.0M in total across 1 funding round.
Launchpad Therapeutics has raised $30.0M in total across 1 funding round.
Launchpad Therapeutics's investors include New Enterprise Associates, Versant Ventures, Aisling Capital, Hbm Partners.
Launchpad Therapeutics has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2022 | $30M Series A | NEW Enterprise Associates, Versant Ventures | Aisling Capital, HBM Partners | Announced |
Launchpad Therapeutics is a precision oncology biotechnology company specializing in AI-driven monoclonal antibody (mAb) design for mutant-selective cancer therapies.[1][2][5] Spun out from Black Diamond Therapeutics in December 2022, it develops early-stage antibody programs targeting genetically defined cancers, leveraging Black Diamond's MAP (Mutation-Allostery-Pharmacology) Drug Discovery Engine to create cancer cell-specific antibodies from sequence to structure to function.[1][4] The company serves oncology patients with limited treatment options by addressing unmet needs in precision medicine, such as overcoming resistance and minimizing toxicities, and secured $30 million in Series A funding from Versant Ventures and New Enterprise Associates (NEA).[3][4] Its growth momentum began with this spinout capital and inherited antibody candidates, positioning it to disrupt antibody drug discovery in oncology and immunology.[1]
Launchpad Therapeutics emerged as a spinout from Black Diamond Therapeutics, a precision oncology company founded in 2018, announced on December 12, 2022.[1][3][4] Black Diamond, facing strategic shifts after abandoning some small-molecule programs like BDTX-189 and focusing on others such as BDTX-1535 and BDTX-4933, created Launchpad to specialize in antibody development using its MAP Drug Discovery Engine.[4] This allowed Black Diamond to retain a minority equity stake while Launchpad pursued an initial portfolio of early-stage, mutant-selective antibody programs.[1][4] Key backers Versant Ventures and NEA, Black Diamond's founding investors, led the $30 million Series A to launch Launchpad in Cambridge, MA, assembling a team of drug hunters, data scientists, machine learning experts, and computational scientists.[1][3] The idea stemmed from recognizing the maturing precision oncology field as ideal for an antibody-focused, cloud-based computational pipeline.[1]
Launchpad stands out in precision oncology through these key strengths:
Launchpad rides the wave of AI-accelerated drug discovery in precision oncology, where computational tools like its MAP Engine address the complexity of targeting mutations across numerous cancer types.[1][2] Timing is critical: as of 2022, precision oncology had matured beyond early small-molecule focus, creating demand for antibody-based therapies that Black Diamond's 2018 launch anticipated but now hones via spinout.[1][4] Favorable market forces include surging VC interest in AI-biotech hybrids (evidenced by its $30M Series A amid Black Diamond's challenges) and unmet needs for brain-penetrant, resistance-beating drugs.[1][4] It influences the ecosystem by validating spinout models for platform tech, enabling focused innovation—Black Diamond sharpens on small molecules while Launchpad pioneers antibodies—potentially expanding patient access to mutation-specific treatments.[1][4]
Launchpad is primed to advance its antibody portfolio into preclinical and IND stages, building on MAP Engine validations like Black Diamond's prior FDA allowances.[2][4] Trends like AI integration in biologics design and rising emphasis on mutant-selective therapies will propel it, especially as oncology shifts toward multi-modal precision attacks on resistant cancers.[1][2] Its influence may grow through partnerships or further spinouts, amplifying Black Diamond's ecosystem impact while scaling novel mAbs. As a 2022 spinout with strong VC backing, Launchpad exemplifies how focused antibody innovation from proven engines can redefine precision oncology trajectories.[1][3]